ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1151

A Comparison of Patients with Cardiac Sarcoidosis vs. Other Systemic Manifestations of Sarcoidosis: A Retrospective Cohort Study
Abstract Number: 2389

A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study
Abstract Number: 0309

A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative
Abstract Number: 1000

A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
Abstract Number: 1626

A Delphi Exercise Informing the Development of Criteria to Measure Response to Treatment in Giant Cell Arteritis
Abstract Number: 2519

A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Abstract Number: 1654

A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts
Abstract Number: 0886

A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
Abstract Number: 1936

A Fully Automated Method for Measuring Minimum Tibiofemoral Joint Space Width in Knee Osteoarthritis Assessment: Data from the FNIH cohort
Abstract Number: 0915

A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Abstract Number: 1135

A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate
Abstract Number: 0041

A genetically determined, serine-based and phosphorylation-dependent molecular switch regulates the inflammatory potential of human IgA
Abstract Number: 1468

A HIPAA-Compliant LLM for Personalized Therapeutic Decision-Making in Lupus Nephritis
Abstract Number: 0182

A Joint Effort: Implementing Depression Screening in a Safety-Net Rheumatology Clinic
Abstract Number: 0846

A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].